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We previously demonstrated that expression of androgen
receptor (AR) by transfection of the androgen-independent
prostate cancer cell line PC3 decreases invasion and adhesion
of these cells (PC3-AR) through modulation of 64 integrin
expression. The treatment with androgens further reduced
invasion of the cells without modifying 64 expression, sug-
gesting an interference with the invasion process by andro-
gens. Here, we investigated EGF-mediated signal transduc-
tion processes that lead to invasion in PC3-AR cells. We show
that EGF-induced EGFR autotransphosphorylation is re-
duced in PC3-AR cells compared to PC3 cells transfected
only with the vector (PC3-Neo). EGF-stimulated PI3K activ-
ity, a key signaling pathway for invasion of these cells, and
EGF-PI3K interaction are also decreased in PC3-AR cells and
further reduced by treatment with androgen. Finally, we
show that EGFR internalization process was reduced in
PC3-AR and LNCaP cells compared to PC3-Neo. Investiga-
tions on the location of AR in PC3-AR transfected cells were
also conducted. Immunoconfocal microscopy and coimmino-
precipitation studies demonstrated the presence of an inter-
action between EGFR and AR at membrane level in PC3-AR
and LNCaP cells. In conclusion, our results suggest that the
expression of AR by transfection in PC3 cells confers a less-
malignant phenotype by interfering with EGFR signaling
leading to invasion through a mechanism involving an inter-
action between AR and EGFR.
© 2004 Wiley-Liss, Inc.
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Prostate Cancer (PC) is one of the most common cancer and the
second leading cause of death in American men.1 Since prostate
cancer cell growth is enhanced by androgens, in the advanced
stages of the disease, androgen ablation therapy represents a valu-
able tool for the treatment of these patients. However the devel-
opment in most patients after few years of treatment of androgen-
independent clones, characterized by higher invasiveness and
metastatic properties, has focused attention on the molecular
mechanisms that lead to loss of androgen-dependence as well as on
the pathways that are regulated by androgens in these cells besides
proliferation. Indeed, although androgens are the major stimulus
for proliferation of prostate cancer cells, maintenance of androgen-
sensitivity appears to keep a more differentiated and less malignant
phenotype of these cells. The ability to produce tumors in nude
mice, for instance, is higher in androgen-insensitive cell lines
(such as PC3 and DU145) with respect to androgen sensitive
(LNCaP).2 In this light, the role of androgens in the regulation of
the pathways involved in invasion and metastasis represents a
major task in studies on prostate cancer biology.3 As a result, some
androgen-regulated genes involved in signaling pathways that lead
to invasion have been recently identified4–6 and their role in
decreasing invasion ability of androgen-sensitive prostate cancer
cells indicated. Migration and invasion of cancer cells is regulated
by multiple pathways that employ various growth factor and their
receptors, integrins and cytoskeletal elements. A key role is played
by the EGF receptor (EGFR), which, following interaction with
the integrin 64, promotes cell migration through activation of
PI3K and other downstream pathways.7,8
In a previous study, we demonstrated that the expression of andro-
gen receptor in PC3 cells by transfection with a full-length human
androgen receptor expression vector (PC3-AR) determined a decrease
in the expression of the integrin 64 and in the ability of these cells
to invade Matrigel in response to EGF.6 The treatment with the
synthetic androgen R1881 determined a further decrease of the inva-
sion ability of these cells, without however modifying the surface
expression of 646 and prospecting an effect of the androgen on
EGF-mediated signaling related to invasion.
In our present study, we investigated EGF-activated signaling in
PC3-Neo and -AR cells. We report that EGF-mediated EGFR
autotransphosphorylation and PI3K activation is reduced in
PC3-AR cells. In addition, we demonstrate colocalization and
coimmunoprecipitation of AR and EGFR in PC3-AR and LNCaP
cells, indicating an interaction between the 2 receptors.
MATERIAL AND METHODS
Antibodies and chemicals
Rabbit polyclonal anti-androgen receptor antibody (N-20) was
obtained from Santa Cruz Biotechnology (Santa Cruz, CA); rabbit
polyclonal anti-androgen receptor antibody (Pa1-110) was ob-
tained from Affinity BioReagents, Inc. (Golden, CO). Rabbit Ab
(4 cyto) was generously provided by Prof. F. Giancotti (Memo-
rial Sloan-Kettering Cancer Center, New York, NY). Mouse MAb
Ab2 (anti EGFR) and mouse MAb Ab1 (anti EGFR) were from
Oncogene (Cambridge, England). Rat MAb anti-4 (439-9B) was
provided by Dr. R. Falcioni (Molecular Oncogenesis Laboratory,
Regina Elena Cancer Institute, Rome, Italy) and mouse anti-human
integrin 4 monoclonal antibody was obtained from Chemicon
International, Inc. (Temecula, CA). Antiphosphtyrosine PY20 an-
tibody was obtained from ICN (Costa Mesa, CA); antiphosphty-
rosine PY99 antibody was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Mouse monoclonal anti PI 3-kinase
p110 (D-4) and anti EGFR (1005) was from Santa Cruz Biotech-
nology. Rabbit polyclonal anti-phospho-AKT (Ser473) antibody
and mouse monoclonal anti-AKT antibodies were from Cell Sig-
naling Technology (Beverly, MA). Recombinant human epidermal
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growth factor (EGF) was obtained from Pepro Tech EC (London,
England). Matrigel was from Collaborative Biomedical Products
(Bedford, MA). The tyrosine kinase inhibitor ZD1839 (“Iressa”)
was a generous gift from Astrazeneca (London, England). The
antibiotic Geneticin (G418), PD 098059 [2-(2-amino-3-methoxy-
phenyl)-oxanaphthalen-4-one] and LY294002 were obtained from
Calbiochem (San Diego, CA). Laminin-1 and other not specified
reagents were from Sigma Chemical Co. (St. Louis, MO).
Cell culture and transfection
PC3 cell line was obtained from American Tissue Culture
Collection (Bethesda, MD) and maintained in HAM-F12 Coon
supplemented with 10% FBS, 1% penicillin/streptomycin and 1%
glutamine. Before stimulation with androgens, cells were kept for
24 hr in serum- and phenol red-free medium. PC3 cells were
transfected with human full length androgen receptor construct
(p5HbhAR) or vector alone (PC3-NEO cells) by electroporation
and selected in the presence of 0.5 mg/ml geneticin (G418) as
described previously.6 To obtain stable colonies, individual clones
were isolated by limiting dilution and tested for the presence of the
androgen receptor both by Northern and Western analysis.6
Flow cytometry analysis
Cell surface EGFR expression was evaluated by flow cytometry
performed as described.6,9 Cells were grown on Petri dish until
confluence, washed with PBS, detached with 0.1% trypsin-EDTA and
resuspended in PBS supplemented with 1 mM CaCl2 and 1 mM
MgCl2. After the indicated treatments, cells were incubated for 30
min at 4°C with the monoclonal anti-EGFR antibody Ab1, or non-
specific IgG as control, washed 3 times with PBS and further incu-
bated with FITC-conjugated goat anti-mouse secondary antibody
(1:200) for 30 min. In some experiments, cells were labeled with
FITC-conjugated EGF (Molecular Probes, Eugene, OR). After wash-
ing 3 times, cells were fixed with 3% paraformaldehyde in PBS. FITC
green fluorescence was detected at 515–555 nm using a FL-1 detector
of a FACScan flow cytometer (Becton Dickinson, Mountain View,
CA) equipped with a 15 mW argon-ion laser for excitation. Debris
were gated out by establishing a region around the population of
interest on the Forward Scatter vs. Side Scatter dot plot. For each
sample, 10,000 events in the region of interest were recorded at a flow
rate of 200–300 cells/sec. Data were processed with analysis software
LYSYS II (Becton Dickinson).
Immunoprecipitation and western blot analysis
Protein extraction and Western blot analysis were performed as
previously described.6,10 Immunoprecipitation was performed as
previously described10 with few modifications. Briefly, cells were
scraped in PBS supplemented with 1 mM Na3VO4, centrifuged
and resuspended in lysis buffer (20 mM Tris, pH 7.4, 150 mM
NaCl, 0.25% NP-40, 0.2% Triton-X and 1 mM Na3VO4, 1 mM
PMSF). After protein measurement, aliquots of cell lysates con-
taining equal amount of proteins (500 g) were incubated for 1 hr
with 30 l of Protein A (or Protein G)-Sepharose for preclearing.
Precleared lysates were then incubated for 1 hr using 5 g of
specific antibodies on ice followed by overnight incubation at 4°C
with 30 l of Protein A (or Protein G)-Sepharose. The immuno-
beads were washed 3 times in lysis buffer and then resuspended in
10 l of 2 reducing sample buffer, boiled and loaded onto 8%
polyacrylamide-bisacrylamide gels. After SDS-PAGE, proteins
were transferred to nitrocellulose membranes. The membranes
were blocked overnight at 4°C in 5% BSA-TTBS (0.1% Tween-
20, 20 mM Tris and 150 mM NaCl). After washing in TTBS, the
membranes were incubated for 2 hr with the different primary
antibodies, followed by incubation with peroxidase-conjugated
relative secondary antibodies. Finally, probed proteins were re-
vealed by enhanced-chemiluminescence system (BM, Roche). Af-
ter the first blotting with peroxidase-conjugated secondary anti-
bodies, nitrocellulose membranes were stripped at 50°C for 30 min
in stripping buffer (100 mM 2-mercaptoethanol, 2% sodium
dodecyl sulphate and 62.5 mM Tris-HCl, pH 6.7) and reprobed
with specific primary antibodies.
Invasion assay
Invasion assays were performed as described previously6,9 ac-
cording to Albini et al.11 using the Boyden chambers equipped
with 8 m porosity polyvinylpyrrolidone-free polycarbonate fil-
ters. A thin layer of Matrigel solution (50 g/ml) was overlaid on
the upper surface of the filter and allowed to gel by incubating the
filters at 37°C for 30 min. Cell ability to invade the substrate was
assessed by using epidermal growth factor (EGF). EGF (100 ng/ml
in DMEM) was added to the bottom well of the Boyden chambers;
105 cells were added to the top of the chambers and incubated for
24 hr at 37°C. Migrated cells were quantitated by counting cells
with a Zeiss microscope (Oberkochen, Germany) equipped with
brightfield optics (40 magnification). Results are expressed as
the number of migrated cells per high-power field.
PI3 kinase assay
Cells were pretreated for 24 hr with R1881 (1 nM) or vehicle alone
(DMSO), detached with 0.05% trypsin-EDTA, blocked with trypsin-
inhibitor and plated on laminin-1 (20 g/ml) coated dishes for 2
hours. Cells were then stimulated with EGF (50 ng/ml 15 min),
scraped in PBS supplemented with 1 mM Na3VO4, centrifuged and
extracted with lysis buffer (20 mMTris, pH 7.4, 137mMNaCl, 1 mM
CaCl2, 1 mM MgCl2, 1% NP-40, 1 mM Na3VO4 and 1 mM PMSF).
PI3K activity was measured as described previously.12,13 After mea-
surement of proteins, the aliquots of cell extracts containing equiva-
lent amount of proteins (500 g) were incubated for 1 hr with 50 l
of Protein G-Sepharose for preclearing. Precleared lysates were then
incubated with an anti-phosphotyrosine MAb (PY99) from Santa
Cruz Biotechnology (Santa Cruz, CA) overnight at 4°C with 50 l of
Protein G-Sepharose as described above. The Sepharose beads were
washed 2 times with lysis buffer and twice with a 10 mM Tris-HCl
(pH 7.4) containing 0.1 mM EGTA and 5 Mm LiCl. After removal of
the last wash, the beads were suspended in kinase buffer (10 mM
Tris-HCl, 150 mM NaCl and 5 mM EDTA) containing 20 g of
L--phosphatidylinositol (Sigma Chemical Co.) 25 mM MgCl2 and
10 Ci of [32P]ATP and incubated for 20 min at room temperature.
The reaction was stopped by the addition of 60l of 6MHCl and 160
l of a mixture of chloroform and methanol (1:1). Lipids were then
resolved by thin layer chromatography plates (TLC silica gel 60)
(Merck, Darmstadt, Germany) in chloroform, methanol, water and
ammonium hydroxide (60:47:11.3:2). Dried TLC sheets were devel-
oped by autoradiography. Quantifications of the bands was performed
using a Kodak image analysis system.
Indirect immunofluorescence microscopy
Glass slides were coated with 20 g/ml of laminin-1 for 2 hr at
37°C and were then blocked with PBS containing 1% heat-inactivated
bovine serum albumin (BSA) at 4°C overnight. Cells were plated
(1106 cells) on the matrix-coated glass slides and allowed to adhere
for 2 hr in a humidified atmosphere with 5% CO2 at 37°C. The cells
were then stimulated with EGF (50 ng/ml 15 min) and subsequently
fixed with 2% paraformaldehyde. In case of staining with anti-AR
antibodies the cells were permeabilized with 0.1% triton-X in PBS.
After fixation, the cells were rinsed in PBS and incubated in a
blocking solution containing 1% albumin and 5% goat serum in PBS
for 30 min. Primary antibodies in blocking solution were added in
combination to the fixed cells and incubated at room temperature for
30 min. After washing in PBS, the immunoreactivity was revealed
using FITC-conjugated or Texas Red- or Rhodamine-conjugated anti
rat, anti-mouse, or anti-rabbit secondary antibodies (minimal cross
reaction inter-species) in blocking buffer (1:50), used separately or in
combination to stain the cells for 30 min. Negative controls were
performed by substituting the primary antibodies with the blocking
buffer. The immunostained cells were rinsed with PBS and mounted
in a mixture (8:2) of glycerol and PBS (pH 8.5). The cells were
observed under a laser scanning confocal microscopy (Bio-Rad MRC
1024 ES, Hercules, CA) equipped with a Krypton/Argon laser source
15 nm. A series of optical sections (512512 pixels) were taken
through the depth of the cells with a thickness of 1 M at intervals of
0.8 M by using a Nikon 60 1.4 oil immersion objective. Each
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section was signal-averaged during acquisition to improve image
quality, using the Kalman averaging option (5 scan), and the entire
series was projected as a single composite image by superimposition.
To reduce bleed-through effects dual channel scanning of red and
green signals were recorded separately and saved in 2 different files.
Statistical analysis
Statistical analysis was performed with ANOVA and Student’s
t-test for unpaired and, when applicable, for paired data.
RESULTS
EGFR autotransphosphorylation in response to EGF is reduced
in PC3-AR cells
Western blot analysis of integrin 4 in PC3-Neo and -AR total
cell lysates (Fig. 1a 4 panel) and following integrin 4 immu-
noprecipitation (Fig. 1a, lower panel) confirms the reduced expres-
sion of the protein in AR positive PC3 cells (Fig. 1).6 In addition,
both experiments demonstrate that 4 protein expression is not
regulated by androgen treatment (R1881, 1 nM, 3 days of treat-
ment) in PC3-AR cells (Fig. 1a 4 and lower panels), confirming
previous results obtained by FACScan analysis.6 The expression of
EGFR is similar in the 2 cell lines and is not modified by treatment
with R1881 (Fig. 1a, EGFR panel) as also confirmed by FACScan
analysis of surface expression of the protein in PC3-AR cells
compared to PC3-Neo (not shown; see also Fig. 7). Stripping and
reprobing of the blot in Fig. 1a (4 panel) with an anti-phospho-
tyrosine antibody (PY20) demonstrates a different pattern of ty-
rosine phosphorylated protein bands in the 2 cell lines (Fig. 1a,
PY20 panel). In particular, although EGF treatment (50 nM, 5 min)
induces an increase in tyrosine phosphorylation in a protein band
FIGURE 1 – (a) Western blot analysis of inte-
grin 4 and EGFR expression in total lysates of
PC3-Neo and PC3-AR cells in basal conditions
(c) and following stimulation with the synthetic
androgen R1881 (R1, 1 nM, 3 days), EGF (50
ng/ml, 5 min) or the 2 agonists together (ER).
The blot was first probed for 4 integrin,
stripped and reprobed with anti-EGFR and fi-
nally with anti-phosphotyrosine PY20 antibody.
In the lower panel, Western blot analysis of
integrin 4 following immunoprecipitation of
the integrin from the lysates of the 2 cell lines in
the same conditions as indicated for (a) is
shown. Both blots are representative of at least
3 different experiments. (b) Western blot anal-
ysis of EGFR tyrosine phosphorylation follow-
ing treatments as described for (a), in PC3-Neo
and PC3-AR cell lysates immunoprecipitated
with anti-EGFR antibody. Cells lysates were
immunoprecipitated (IP) using an anti-EGFR
antibody (Ab-1), run by SDS-PAGE and immu-
noblotted (IB) with anti-phosphotyrosine
(PY20, upper panel), and anti-EGFR (Ab-2,
lower panel) antibodies. IgG: negative controls
(immunoprecipitated with control IgG). C 
control conditions. Representative of 3 similar
experiments. (c) Densitometric analysis of ty-
rosine phosphorylation of EGFR (reported as
the ratio between EGFR tyrosine phosphory-
lated band/EGFR band) in response to EGF in
presence or absence of R1881 of 4 different
immunoprecipitation experiments in PC3-Neo
and PC3-AR cells. *p	0.005 vs. the same treat-
ment in PC3-Neo cells. #p	0.05 vs. EGF in
PC3-AR cells
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of about 180 kDa, comigrating with EGFR, in both cell lines (Fig.
1a, PY20 panel), such increase appears to be reduced in PC3-AR
cells, in particular in the presence of R1881. To confirm that the
observed increase of tyrosine phosphorylation in the 180 kDa
protein band in response to EGF corresponds to autotransphospho-
rylation of the EGFR, the latter was immunoprecipitated in both
cell lines. As shown in Figure 1b (PY20 panel), EGF induces
autotransphosphorylation of EGFR is reduced in PC3-AR cells
compared to PC3-Neo and treatment with R1881 (10 nM, 3 days)
further reduces it (Fig. 1b; see also Fig. 3). Densitometric analysis
of the ratio between EGFR tyrosine phosphorylated band and
EGFR band from 4 different experiments performed by immuno-
precipitation in the 2 cell lines is reported in Figure 1c. These
results confirm reduced EGFR autotransphosphorylation in
PC3-AR cells in the presence of R1881 and respect to PC3-Neo.
Overall, these data suggest that the presence of an active androgen
receptor interferes with EGFR signaling in PC3 cells.
The androgen receptor co-localizes and co-immunoprecipitates
with the EGFR in PC3-AR cells
Emerging evidence indicates that besides its classical location at
the nuclear level, the AR may be targeted at the membrane, where
interactions with proteins involved in growth factor signaling, such
as src kinase family members,14 caveolin-115 and PI3K16 have
been demonstrated. We investigated the localization of AR in our
cell line by confocal laser microscopy in PC3-AR cells stained for
both AR and EGFR. As shown in Figure 2 the AR (in red, middle
panels) localizes both to the nucleus and the cytoplasm of PC3-AR
cells, although after stimulation with R1881, increased location to
the nuclei was evident. The presence of some nuclear staining in
PC3-AR also in control conditions is in agreement with results
obtained by other authors in PC3 cells transfected with AR.17
Interestingly, a striking colocalization (in yellow, right panels) of
the AR with the EGFR (in green, left panels) at plasma membrane
level was present. In response to EGF, colocalization between the
EGFR and the AR was also evident at the level of intracellular
granules, possibly reflecting internalization vesicles of the
EGFR-AR complex. When cells are stimulated with EGF in the
presence of R1881, the pattern of colocalization between the 2
proteins appears to be different compared to EGF alone since
much less vesicles are present (Fig. 2). Similar results were ob-
tained in the another PC3-AR clone (not shown). No staining for
AR was present in PC3-Neo cells (Fig. 2, lower panels). To
FIGURE 2 – Confocal microscopy analysis of localization of the androgen receptor (AR) and EGFR in PC3-AR cells. PC3-AR cells were
pretreated or not with the synthetic androgen R1881 (1 nM, 3 days), plated on laminin-1 for 2 hr and then stimulated with EGF (50 ng/ml) or
vehicle (C) for 15 min. Cells were permeabilized and processed for double staining with rabbit polyclonal anti-AR (N-20) (red) and anti-EGFR
(Ab-1) (green) antibodies. Yellow depicts colocalization of the 2 antibodies. Lower panel, PC3-Neo cells were plated on laminin-1 for 2 hr and
then were processed for double staining with anti-AR (N-20) (red) and anti-EGFR (Ab-1) (green) antibodies. Representative of 3 similar
experiments.
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demonstrate that the colocalization between the AR and EGFR
observed in PC3-AR cells is due to an association of the 2
molecules, coimmunoprecipitation studies using both anti-EGFR
and anti-AR antibodies were conducted. As shown in Figre 3a
after immunoprecipitation with an antibody against EGFR, a band
at 110 kDa was detected by immunoblot analysis with an anti-AR
antibody in PC3-AR cells. A tyrosine phosphorylated band corre-
sponding to EGFR was also detected (Fig. 3a). Similarly, follow-
ing immunoprecipitation of AR in PC3-AR cells, EGFR was
detected by immunoblotting (Fig. 3b). Interestingly, EGF induced
tyrosine phosphorylation of EGFR was reduced in PC3-AR cells in
both experimental conditions (Fig. 3a,b), in particular in the pres-
ence of R1881 (see also Fig. 1b). Coimmunoprecipitation between
the EGFR and AR was also detected in the cell line LNCaP, which
physiologically express the AR (Fig. 3c). As shown in the figure,
following immunoprecipitation of EGFR, a band corresponding to
AR was found. Stripping and re-probing of the blot with an
anti-phosphotyrosine antibody demonstrated that the treatment
with R1881 determined a decrease in EGFR autotransphosphory-
lation also in this cell line (Fig. 3c), in agreement with results
obtained in PC3-AR cells (Fig. 3a,b). In the lanes treated with EGF
a decrease in co-immunoprecipitated AR protein was observed
(Fig. 3c). This results, consistently found in LNCaP cells, is
difficult to explain. One possibility is that in this cell line the
receptor may somehow escape from interaction with AR following
treatment with EGF. Overall, results shown in Figures 2 and 3
indicate that an interaction between EGFR and AR occurs in andro-
gen-sensitive prostate carcinoma cells and that this interaction may be
involved in determining a decreased signaling ability of EGFR (this
manuscript) and the decreased invasive ability of these cells.6,18
EGF-induced activation of PI3K is reduced in PC3-AR cells
As mentioned above, EGF promotes the activation of distinct
signaling pathways in cancer cells, including PI3K,7 which finally
leads to cell migration and invasion. To evaluate whether PI3K
activation is involved in Matrigel invasion of PC3-Neo cells,
invasion assays were performed in the absence or presence of the
PI3K inhibitor LY294002 (80 M). As shown in Figure 4, EGF-
induced invasion through Matrigel was inhibited by pretreatment
(30 min) with LY294002, indicating that the activation of PI3K
pathway is essential for EGF-dependent invasion. Matrigel inva-
sion in response to EGF was also suppressed by ZD1839 (also
known as “gefitinib” and “Iressa”, 10 M), a tyrosine kinase
FIGURE 3 – (a) Western blot analysis of EGFR and AR, EGFR
tyrosine phosphorylation in response to EGF (50 ng/ml, 5 min) in the
presence or absence of the synthetic androgen R1881 (R1, 1 nM, 3
days) in PC3-Neo and PC3-AR cell lysates immunoprecipitated with
anti-EGFR antibody. Cells lysates were immunoprecipitated (IP) using
an anti-EGFR antibody (Ab-1), run by SDS-PAGE and immunoblotted
(IB) with anti-AR (N-20) (upper panel), anti-EGFR (Ab-2) (middle
panel), anti-phosphotyrosine antibody (PY20, lower panel) antibodies.
IgG: negative controls (immunoprecipitated with control IgG). C
control conditions. Representative of three similar experiments. (b)
Western blot analysis of EGFR and AR, EGFR tyrosine phosphory-
lation after treatments as described for (a) in PC3-AR cell lysates
immunoprecipitated with anti-AR antibody. PC3-AR cells lysates
were immunoprecipitated (IP) using an anti-AR antibody (Pa1-110)
and blotted (IB) with an anti-phosphotyrosine (PY20, upper panel) and
anti-EGFR (Ab-2, lower panel) antibody. Representative of 2 similar
experiments. (c) Western blot analysis of EGFR and AR, EGFR
tyrosine phosphorylation in response to EGF (50 ng/ml, 5 min) in the
presence or absence of the synthetic androgen R1881 (R1, 1 nM, 3
days) in LNCaP cell lysates immunoprecipitated with anti-EGFR
antibody. LNCaP cells lysates were immunoprecipitated (IP) using an
anti-EGFR antibody (Ab-1) and blotted (IB) with an anti-EGFR (Ab-2,
upper panel), anti-phosphotyrosine (PY20, middle panel) and anti-AR
(N-20) (lower panel). Representative of 2 similar experiments.
FIGURE 4 – Effect of different kinase inhibitors on Matrigel invasion
of PC3-Neo cells. Matrigel was diluted in DMEM (50 mg/ml) and
overlaid on the upper surface of the polycarbonate filter. EGF (100
ng/ml) or DMEM were added to the bottom wells of the boyden
chambers. Cells (105), untreated or treated with the PI3K inhibitor
LY294002 (80 mM, LY), the MAPK cascade inhibitor PD098059 (50
mM, PD) and the EGFR tyrosine kinase inhibitor ZD1839 (“Iressa”)
(10 mM) were added to the top of the wells of the chambers and then
incubated for 24 hr at 37°C. The cells that reached the lower surface
were quantitated by light microscopy. Values are expressed as
mean
SEM of the indicated number of experiments. **p	0.05 vs.
control (C), °p	0.05 vs. EGF
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inhibitor selective for EGFR19 (Fig. 4). On the contrary, we found
that PD098059 (50 M, 30 min) an inhibitor of MAPK signaling
cascade20 did not affect Matrigel invasion in response to EGF (Fig.
4), indicating that this pathway is not involved in EGF-mediated
invasion in PC3 cells. To investigate whether PI3K activity was
altered in PC3-AR cells, cell lysates from PC3-Neo and PC3-AR
cells, stimulated or not with EGF (50 ng/ml), were immunopre-
cipitated with an anti-phosphotyrosine antibody to recruit the
activated fraction of PI3K and assayed for their ability to phos-
phorylate L--phosphatidylinositol. As shown in Figure 5, both
basal and EGF-stimulated PI3K activity are reduced in PC3-AR
cells with respect to PC3-Neo. Pretreatment with R1881 deter-
mined a decrease of EGF-stimulated PI3K activity in PC3-AR
cells, whereas it was ineffective in PC3-Neo cells. Figure 5, lower
panel, reports mean
SEM values of PI3K activity (measured by
quantification of the bands) of 4 different experiments. This result
suggests that in the presence of an AR, PI3K activity of PC3 cells
is reduced, in line with recent results that demonstrate that losing
dependence or sensitivity from androgens, such as in LNCaP cells
in high passages21 or following androgen deprivation,22 leads to
higher activity of PI3K respect to cells expressing a more differenti-
ated phenotype (LNCaP at early passages or androgen-sensitive).
In carcinoma cells, constitutive activation of PI3K is often found.23
PI3K is activated by the interaction of the p85 subunit with phosphor-
ylated tyrosine residues on activated growth factor receptors including
the EGFR.24 To study whether the reduced basal and EGF-stimulated
PI3K activity in PC3-AR cells is due to an impairment of PI3K-EGFR
interaction, we immunpreciptated PI3K from PC3-Neo and -AR cells
using an anti-p110 PI3K antibody and evaluated coimmunoprecipi-
tation with EGFR in both cell lines. As shown in Figure 6a, although
p110 PI3K expression was similar in the 2 cell lines, the fraction of
EGFR coimmunoprecipitating with PI3K was much higher in PC3-
Neo cells, suggesting an impairment of EGFR-PI3K interaction in the
presence of the AR. In addition, when the blot was probed using an
anti-phosphotyrosine antibody, a phosphorylated protein band at 180
kDa molecular weight, comigrating with EGFR, was detected only in
PC3-Neo cells (Fig. 6a). However, treatment with EGF does not
appear to modify either tyrosine phosphorylation of this band or
EGFR-PI3K interaction (Fig. 6a). This result was constantly repro-
duced in 3 different experiments.
To confirm that PI3K activation is reduced in PC3-AR cells, we
performed Western blot analysis of total lysates from PC3-Neo
and PC3-AR cells using anti-phosphoserine AKT antibodies. As
FIGURE 5 – Phosphatidylinositol-3 kinase (PI3K) activity in response to EGF and R1881 in PC3-Neo and PC3-AR cells. (upper panel)
PC3-Neo and PC3-AR cells, pretreated or not with R1881 (R1, 1 nM, 24 hr), were plated on laminin-1 for 2 hr and then stimulated with EGF
(50 ng/ml). Cell lysates were immunoprecipitated with an anti-phosphotyrosine antibody (PY99) and PI3K activity measured as described in
Material and Methods. (lower panel) Mean
SEM values of PI3K activity (arbitrary units) in 3 different experiments.
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shown in Figure 6b (upper panel) treatment with EGF induces
AKT phosphorylation in PC3-Neo but not in PC3-AR cells,
whereas AKT expression was similar in both cell lines (Fig. 6b
lower panel), confirming reduced activation of the PI3K/AKT
pathway in PC3-AR cells. The lower mobility of AKT band in the
lanes treated with EGF in PC3-Neo cells may reflect a shift due to
increased phosphorylation (Fig. 6b upper panel).
EGFR internalization is altered in PC3-AR cells
Following EGF treatment, EGFR is rapidly downregulated from
the cell surface undergoing a process of internalization/endocyto-
sis.25 As shown in Figure 4, in PC3-AR cells, EGFR is located at
the level of discrete vesicles, probably reflecting internalization of
the receptor. However, the presence of these vesicles was reduced
when treatment with EGF was performed in the presence of R1881
(Fig. 2), suggesting an impairment of the process of EGFR inter-
nalization. To further investigate EGFR internalization process in
our cell model, we performed FASCan analysis of surface EGFR
expression following treatment with EGF (50 ng/ml, 15 min incu-
bation) in the presence or absence of R1881 (1 nM) in PC3-Neo
and -AR cells. As shown in Figure 7a, when PC3-Neo cells were
incubated with EGF at 37°C, a significant decrease in cell surface
expression of the receptor was detected, as evidenced by the shift
of the positive peak to the left. In PC3-AR cells the shift of the
peak to the left was dramatically reduced, indicating decreased
internalization. Treatment with R1881 (1 nM) further reduced
EGFR internalization induced by EGF in PC3-AR cells but did not
affect receptor internalization in PC3-Neo cells (Fig. 7a). Mean
(n2) percentage of cells expressing EGFR on the surface respect
to control in the 2 cell lines in the different conditions are reported
in Figure 7b. Similar results were obtained by using FITC-conju-
gated EGF to label surface EGFR (data not shown). In analogy
with results obtained in PC3-AR cells, EGFR internalization was
found to be reduced also in LNCaP cells when compared to
PC3-Neo cells. Indeed, following EGF treatment, surface EGFR
expression in LNCaP cells was reduced only of 25% (not shown), a
value similar to the 22% decrease observed in PC3-AR cell (Fig. 7b).
DISCUSSION
Increasing evidence demonstrates that androgen-responsive
prostate cancer cells are characterized by reduced growth, adhe-
sion, invasion, migration and colony-forming abilities,2,6,17,26 sug-
gesting that maintenance of an AR-sensitive phenotype reduces the
malignant potential of these cells. In addition, the presence of a
functional AR in PC3 cells confers sensitization to anticancer
therapy.26 Similarly, in another hormone-dependent cancer, such
as breast cancer, the presence of estrogen receptors maintains a
less invasive phenotype of the cells even in the absence of li-
FIGURE 6 – (a) Western blot analysis of p110 PI3K subunit, EGFR
and tyrosine phosphorylation in response to EGF (50 ng/ml, 5 min) in
the presence or absence of the synthetic androgen R1881 (R1, 1 nM,
3 days) in PC3-Neo and PC3-AR cell lysates immunoprecipitated with
anti-p110 PI3K antibody. Cells lysates were immunoprecipitated (IP)
using an anti-p110 antibody, run by SDS-PAGE and immunoblotted
(IB) with anti-p110 PI3K (upper panel), anti-EGFR (Ab-2) (middle
panel), anti-phosphotyrosine antibody (PY20, lower panel) antibodies.
Representative of three similar experiments. (b) Western blot analysis
of AKT phosphorylation, in response to EGF (50 ng/ml, 5 min) in the
presence or absence of the synthetic androgen R1881 (R1, 1 nM, 3
days) in PC3-Neo and PC3-AR cell total lysates. The blot was first
probed with anti p-ser AKT antibody followed by stripping and
reprobing with anti-AKT antibody. C control. Representative of 3
similar experiments.
FIGURE 7 – Effect of R1881 on internalization of EGFR in PC3-Neo
and PC3-AR6 cells. (a) PC3-Neo and PC3-AR cells were left un-
treated (C) or incubated with R1881 (1 nM, 3 days). Cells were then
incubated with EGF (50 ng/ml) or vehicle for 20 min at 37°C to allow
internalization of the EGFR, placed on ice and processed for detection
of EGFR expression (solid histograms) by flow cytometry analysis as
described in Material and Methods. Nonspecific fluorescence (open
histograms shown in the control panels) was assessed by omitting
incubation with the primary antibody. (b) Average (n2) percentage
cells expressing EGFR on the surface respect to control in PC3-Neo
and PC3-ARcells in the different experimental conditions.
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gands.27–29 Previous results from our6 and other groups30 demon-
strated that, at least in part, decreased in vitro Matrigel invasion of
androgen-sensitive PC cells18 is due to decreased expression of
surface integrins. Other studies performed in androgen-indepen-
dent and -dependent PC cell models in vitro, demonstrated regu-
lation, by androgens, of several other genes involved in modulat-
ing invasion ability of these cells, including prostin-1,31 urokinase-
type palsminogen activator32 and neutral endopeptidase (NEP).5
Here we show that EGF-mediated autotransphosphorylation of
EGFR and downstream PI3K/AKT pathway activation are also
reduced in androgen-sensitive cell lines. In addition, we demon-
strate the occurrence of an interaction between the AR and the
EGFR at the membrane level in the same cell lines. The reduced
autotransphosphorylation of EGFR in androgen-responsive
PC3-AR cells respect to unresponsive cells is in line with previ-
ously published results that show an inverse correlation between
phosphotyrosine levels of ErbB-2, an EGFR mutant, and androgen
responsiveness of prostate cancer cells.33
Recent data demonstrate that the AR may interact with mem-
brane proteins that activate signaling pathways such as ERKs and
PI3K.14,16,34 These mechanisms of androgen receptor signaling are
believed to represent alternative pathways for stimulation of pros-
tate carcinoma cell growth. Our data demonstrate that in PC3-AR
cells the AR colocalizes with the EGFR at the membrane level
through an interaction of the 2 proteins as demonstrated by coim-
munoprecipitation studies performed in the 2 androgen-sensitive
cell lines PC3-AR and LNCaP. Further studies are needed to
evaluate the site and the mechanisms that determine the associa-
tion between AR and EGFR in prostate carcinoma cells. Recently,
the AR has been shown to associate with src kinase family mem-
bers14 and caveolin-115 in PC cell lines. More recently, an asso-
ciation with the signaling protein calmodulin has been also shown
in LNCaP cells.35 In the case of src, the interaction is due to a
proline-rich region in the AR,14 whereas in the case of caveolin-1
both the NH2-terminal and ligand-binding domains of the AR are
involved.15 Both src and caveolin-1 are capable of interacting with
EGFR and are involved EGF-stimulated signaling.36–38 It is thus
possible that EGFR-AR interaction detected in our study is medi-
ated by these proteins. Of interest, the interaction between caveo-
lin-1 and EGFR results in inhibition of ERK activation, lamelli-
podia formation and cell migration of mammary carcinoma cells39
and caveolin-1 expression inhibit invasiveness in the same cells.40
The occurrence of a possible interaction between AR and caveo-
lin-1 and the formation of a complex among AR, caveolin and
EGFR is currently under investigation in our Lab. We prospect a
scenario where interaction between AR and EGFR provokes a
disruption of the mechanisms leading to autotransphosphorylation
of the receptor and PI3K activation in response to EGF leading to
decreased invasion of these cells. It is possible that the interaction
between the 2 proteins may occur at sites that are fundamental for
interaction with other downstream signaling molecules such as
PI3K. On the other hand, our coimmunoprecipitation studies with
anti-PI3K antibodies suggest that EGFR-PI3K interaction is dis-
rupted in PC3-AR cells, possibly explaining the lower activity of
the enzyme in PC3-AR cells. Decreased PI3K activation may be
thus responsible for the described lower aggressive behavior of
PC3-AR, LNCaP and other androgen-sensitive cell lines.2,6,17,25,41
In agreement with our data that shows reduced PI3K/AKT activa-
tion in androgen-sensitive PC3 cells, recent results from different
groups demonstrate that losing dependence or sensitivity from
androgens, such as in LNCaP cells in high passages21 or following
androgen deprivation22 leads to higher activation of PI3K/AKT
respect to cells expressing a more differentiated phenotype (LN-
CaP at early passages or androgen-sensitive).
Our data on EGFR internalization demonstrate that a consider-
able amount of EGFR remains on the surface after treatment with
EGF in PC3-AR cells compared to PC3-Neo, indicating a disrup-
tion of the endocytotic process in our cells. The internalization of
EGFR is further decreased by treatment with R1881. The molec-
ular mechanism responsible for reduced internalization of EGFR
in androgen-sensitive cells is obscure. Recently it has been shown
that EGFR signaling intensity determines the rate of internalization
of the receptor.42 In particular, Schmidt et al.42 showed that if
autotransphosphorylation of EGFR is reduced below a threshold, a
reduction of internalization and downregulation of the receptor
occurs. We show here that EGFR autotransphosphorylation is
reduced in PC3-AR cells and therefore it is possible that also
internalization is consequently reduced. Although internalization
by endocytosis has been assumed to be a mechanism to attenuate
the signaling in response to the growth factor, increasing evidence
demonstrates that a correct endocytotic pathway is important for
EGFR signaling by controlling the specificity of the response.36,37
Several studies have shown that internalized EGFR are enzymat-
ically active, are still phosphorylated and maintain association with
many adaptor proteins.43–45 In addition, it has been recently shown
that interaction with some adaptor proteins, such as eps8, a protein
involved in cytoskeletal reorganization and actin remodeling,46
occurs only at endosomal level.46 Furthermore, blocking of EGFR
endocytosis by using a dynamin mutant results in downregulation
of ERK and PI3K activation in response to EGF47 and insulin.48
Whether EGFR-AR interaction may be responsible for decreased
EGFR signaling and internalization remains to be addressed; how-
ever, it is possible that such interaction disrupts the ability of the
receptor to autophosphorylate by attenuating its intrinsic tyrosine
kinase activity, determining as a consequence a reduction of in-
ternalization and PI3K activation.
It must be mentioned that AR expression is found in a high
percentage androgen-independent PC tumors, although increased
DNA methylation of the AR promoter is found in the latter respect
to androgen-dependent tumors (for review, see reference 49).
However, although these results indicate that expression of AR
protein is not frequently lost, it is possible that the function of the
receptor or the pathways that are regulated by it are altered in
androgen-independent PC. On the other hand, bypassing the AR
via other cellular pathways has been indicated as one of the
possible mechanisms of transition to androgen-independence.50
In conclusion, androgens and AR contribute to confer a less
malignant phenotype of androgen-sensitive prostate tumors, by
reducing the expression of 64 as demonstrated previously,6 and
by interfering with EGFR-64 interaction and signaling leading
to invasion through an interaction between AR and EGFR.
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